Researchers developed a 220-sample pan-cancer patient-derived organoid platform that faithfully mirrors tumors, identifies new treatment opportunities, and advances precision oncology by enabling personalized drug testing. The post Patient-Derived Tumor Organoids Show Promise for Personalizing Cancer Treatment appeared first on GEN – Genetic Engineering and Biotechnology News.
You may also like
Ariane de Ganck
Jasper Therapeutics merges with Kira Pharmaceuticals
Lilly to acquire AtaiBeckley in deal worth $2.8bn
Camena Bioscience appoints Gregory McGuinness as CEO
New €25 Million BioReliance Testing Facility Opens...
StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
